

SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor

Idrees Mohammed, Maloy K Parai, Xinpeng Jiang, Natalia
Sharova, Gati Krushna Singh, Mario Stevenson, and Tariq M. Rana

ACS Med. Chem. Lett., **Just Accepted Manuscript** • DOI: 10.1021/ml300037k • Publication Date (Web): 14 May 2012

Downloaded from <http://pubs.acs.org> on May 15, 2012

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor

Idrees Mohammed,^{[a]†} Maloy K. Parai,^[a] Xinpeng Jiang,^[a] Natalia Sharova,^[b] Gatikrushna Singh,^[a] Mario Stevenson,^[b] Tariq M. Rana^{*[a]}

^[a] Program for RNA Biology, Sanford-Burnham Medical Research Institute, La Jolla, California 92037 (USA)

^[b] Division of Infectious Diseases, Miller School of Medicine, University of Miami, Miami, FL 33136 (USA)

ABSTRACT: We describe structure-activity relationship and optimization studies of RN-18, an HIV-1 Vif-APOBEC3G axis inhibitor. Targeted modifications of RN-18 ring-C, ring-B, ring-A, bridge A-B, and bridge B-C were performed to identify the crucial structural features, which generated new inhibitors with similar (**4g** and **4i**) and improved (**5**, **8b**, and **11**) activities. Two potent water-soluble RN-18 analogues, **17** and **19**, are also disclosed, and we describe the results of pharmacological studies with compound **19**. The findings described here will be useful in the development of more potent Vif inhibitors and in the design of probes to identify the target protein of RN-18 and its analogues.

KEYWORDS: RN-18, HIV-1 Vif-APOBEC3G axis inhibition, structure-activity relationship and optimization, pharmacological studies

Chemotherapies that target inhibition of HIV-1 proteins, in particular HIV-1 protease¹ and reverse transcriptase², have been of immense help in prolonging the lives of patients with acquired immunodeficiency syndrome (AIDS). However, the high rate of HIV-1 replication has led to the emergence of drug resistant strains that remain a major challenge in the field of anti-HIV chemotherapy. Considerable effort is being focused on understanding the structural basis of HIV-1 multidrug resistance (MDR)³ and to develop new inhibitors that are effective in HIV-1 MDR mutants.⁴ In this regard, we recently reported the discovery of small molecule inhibitors of HIV-1 viral infectivity factor (Vif).⁵

HIV-1 mainly infects CD4⁺ T lymphocyte *in vivo*; thus, if the infection is not controlled the immune system becomes seriously weakened and AIDS develops. Efficient HIV-1 replication requires expression of Vif protein to counter the activity of APOBEC3G (A3G), a DNA-editing cytidine deaminase expressed in certain host cells. A3G catalyzes critical hypermutations in the viral DNA and acts as an innate weapon against retroviruses.⁶ Cells that express A3G are 'non-permissive' for viral replication in which HIV-1 must express Vif in order to replicate. In contrast, HIV-1 replication is Vif-independent in host cells that do not express A3G (permissive cells). Vif protein hinders A3G packaging into virions and promotes ubiquitin-proteasomal degradation of A3G.⁷ Therefore, the development of small molecules that inhibit Vif-mediated degradation of A3G in non-permissive T cells is an exciting component of the anti-HIV drug discovery program.

We previously disclosed the structures of 25 Vif antagonists (RN-1 to RN-25) and reported their median inhibitory concentrations (IC₅₀) for inhibition of A3G degradation in non-permissive cells. The compounds were then examined for their capacity to inhibit Vif activity and the replication of wild-type HIV-1 in A3G-expressing non-permissive H9 and CEM cells or in permissive MT4 and CEM-SS cells. Among the 25 compounds, RN-18 and RN-19 exhibited potent antiviral activity in the non-permissive H9 and CEM cells, but not in MT4 or CEM-SS cells, confirming that


the antiviral activity was Vif specific. RN-18 showed the greater potency (IC₅₀ 4.5 μM in CEM cells) and specificity (IC₅₀ >100 μM in MT4 cells) among the two compounds and was therefore selected for further study.⁵

Based on this discovery, we have initiated two projects: (1) lead optimization studies of RN-18 to improve its activity and pharmacological profile, and (2) the identification and validation of RN-18 target protein. In this communication, we describe our initial efforts in the area of structure-activity relationships (SAR) and optimization of RN-18.

For convenience, we refer to the structural components of RN-18 as ring-A, ring-B, ring-C, bridge A-B (thioether linker), and bridge B-C (amide linker). RN-18 (**1**) was synthesized by a conventional acid chloride route (Scheme 1A). *S*-arylation of 4-nitrofluorobenzene with thiosalicylic acid under basic and reflux conditions yielded intermediate acid **2**, which was converted to corresponding acyl chloride. This was reacted with *o*-anisidine in the presence of Et₃N base to yield the lead molecule **1** quantitatively. In the same way, a series of substituted anilines (**3a-k**, Table 1S in the supporting information) were reacted with the acyl chloride of intermediate **2** in a parallel synthetic format to generate a variety of ring-C substituted analogues, **4a-k** (see Table 1 for structures and activities of **4f**, **4g**, **4i** and Table 2S for **4a-e**, **4h**, and **4j-k**). In the ring-C studies, we noticed that methoxy at R₁ is preferred for the antiviral activity. However, from the list of **4a-k** RN-18 ring-C analogues (Table 1 and Table 2S), 2-iodo analogue **4g** and methanesulfonate analogue **4i** showed IC₅₀ values of 4.3 μM and 5.6 μM, respectively, which are similar to the lead molecule. Similarly, from three R₂ substitutions tested (methyl, **4a**; bromo, **4e**; and methyl carboxylate, **4f**) in the presence of methoxy as the R₁ substituent on ring-C, only the methyl carboxylate functionality (**4f**) retained appreciable activity (IC₅₀ of 10 μM).

We next performed SAR studies associated with bridge A-B. The thioether (sulfide) linker present in the lead molecule was oxidized directly using a published method⁸ to afford sulfone **5** (Scheme


1B). Compound **1** was treated with potassium permanganate adsorbed on manganese dioxide, which yielded sulfone **5** as the sole product. Interestingly, we found the activity of the sulfone (**5**) was approximately five-fold greater than the sulfide (**1**), with the sulfone **5** exhibiting an IC_{50} of 1.1 μ M. To continue SAR on bridge A-B, the thioether linker was extended by a CH_2 attached to ring-B (Scheme 4S). However, this extension of bridge A-B reduced the potency of the compound to an IC_{50} of 51 μ M. Similarly, changes involving amide or urea linkers at bridge A-B and reverse amides at bridge B-C yielded relatively inactive compounds (Scheme 5S and Table 3S).

Scheme 1^a

^aReagents and conditions: (a) 4-Fluoronitrobenzene, K_2CO_3 , DMF, 120 °C, 8 h. (b) $SOCl_2$, cat. DMF, benzene, 80 °C, 2 h. (c) *o*-anisidine, Et_3N , benzene, 80 °C, 5 h. (d) **3a-k** (see Table-1S in the supporting information), Et_3N , Benzene, 80 °C, 5 h. (e) $KMnO_4$ /manganese dioxide, CH_2Cl_2 , room temperature, 12 h. (f) 4-nitrothiophenol, DMF, 100-120 °C. (g) 4-nitrothiophenol, K_2CO_3 , 5 mol% CuI, DMF, 100 °C, 6 h. (h) lithium hydroxide monohydrate, THF/MeOH/ H_2O (4:2:1), R.T., 5 h.

To perform SAR studies associated with ring-B, we initially synthesized two pyridine derivatives as outlined in Scheme 1C. Commercially available 2-chloronicotinic acid **6a** and 2-chloro-6-methylnicotinic acid **6b** were converted to acyl chlorides and

separately coupled with *o*-anisidine in basic conditions to obtain intermediates **7a** and **7b**. Compounds **7a** and **7b** were then *S*-arylated with 4-nitrothiophenol in the absence of base, yielding RN-18 pyridine analogues **8a** and **8b**. Substitution of CH with N adjacent to the thioether-linked carbon in ring-B was well tolerated (Table 1, **8a** and **8b**); in the case of compound **8b**, which has a methyl group at position 6 of the pyridine ring, the activity was improved to an IC_{50} of 1.5 μ M. Of note, we discovered an interesting reaction while attempting *S*-arylation of compounds **7a** and **7b** in the presence of potassium carbonate base in refluxing DMF. We observed formation of an unexpected compound instead of the desired products **8a** and **8b**, which could be explained by a cascade reaction involving simultaneous steps of amide hydrolysis, C-S bond fission, and *N*-arylation (see Scheme 10S in the supporting information file). Further exploration of this new reaction is in progress.












Scheme 2^a

^aReagents and conditions: (a) Methyl 4-mercaptobenzoate, cat. CuI, K_2CO_3 , DMF, 110 °C, 8 h. (b) $SOCl_2$, cat. DMF, benzene, 80 °C. (c) *o*-anisidine, Et_3N , benzene, 80 °C, 6 h. (d) $KMnO_4$ /manganese dioxide, CH_2Cl_2 , room temperature, 12 h. (e) $(CH_3)_3SnOH$, 1,2-dichloroethane, 80 °C, 6 h, room temperature, 5 h. (f) choline base 45% in methanol, EtOAc or acetone, room temperature.

A potent compound (**11**) was obtained by changing the point of attachment of the thioether link (bridge A-B) from the *ortho* position (as in RN-18) to the *para* position of ring-B and by placing a chloro group at the *ortho* position of ring-B (Scheme 1D). The synthetic scheme for **11** was started by selective mono *S*-arylation of commercially available methyl 2-chloro-4-iodobenzoate with 4-nitrothiophenol in the presence of copper (I) iodide as a catalyst and potassium carbonate⁹, which yielded the intermediate ester **9**. The methyl ester was hydrolyzed using lithium hydroxide monohydrate to afford *S*-arylated chloro acid **10**, which was then coupled with *o*-anisidine through the acid chloride route to obtain the RN-18 analogue **11**. The antiviral studies of analogue **11** showed an improved IC_{50} of 2.5 μ M. The activity profile of **11** prompted us to examine whether ring-A and bridge A-B were required at all for antiviral activity. To address this, we synthesized **12** (Scheme 1E) by coupling commercially available 2-chlorobenzoic acid with *o*-anisidine using the acid chloride route. However, **12** did not exhibit antiviral activity selectively in non-

permissive H9 cells. Similarly, SAR involving methyl or benzyl moieties on ring-B and sulfonamide, amide, urea, or amine linkages for bridge A-B resulted in compounds with either very low or no activity (Scheme 6S and Table 3S).

Table 1: Antiviral activities of selected compounds

Compound	Antiviral activity (IC ₅₀ μM) H9 cells	MT4 cells
 RN-18, 1	6	N.A.
 4f	10	N.A.
 4g	4.3	N.A.
 4i	5.6	N.A.
 5	1.1	N.A.
 8a	10	N.A.
 8b	1.5	N.A.
 11	2.5	N.A.
 12	N.A.	>50
 17	1.0	N.A.
 19	10	N.A.

N.A. = No Activity




Figure 1: Vif antagonists inhibit HIV-1 replication in non-permissive H9 cells but not in permissive MT4 cells. H9 and MT4 cells (2×10^5 cells per well in 48-well plates) were treated overnight with various concentrations of Vif antagonists (activity graphs are shown here for RN-18 (A), 5 (B), 8a (C), 8b (D), and 19 (E)) before infection with an X4-tropic HIV-1 variant (HIV-1_{LAI}). Cells were maintained in the presence or absence of Vif antagonists for 10-15 days. Viral replication was monitored every other day by measuring reverse transcriptase (RT) activity in culture supernatants.

Studies on ring-A were directed mainly at finding a suitable replacement for the nitro functionality present in the lead molecule 1. To address this, we explored methyl carboxylate, carboxylic acid, and choline carboxylate groups on ring-A, due to their structural similarity with nitro functionality. 2-iodobenzoic acid was *S*-arylated with methyl 4-mercaptobenzoate using copper (I) iodide as a catalyst, yielding an intermediate carboxylic acid 13. This was coupled with *o*-anisidine using the acid chloride route to afford methyl benzoate derivative 14 (Scheme 2A). Compound 14 was hydrolyzed using an excess of trimethyltin hydroxide in refluxing 1,2-dichloroethane solvent¹⁰ leading to the formation of carboxylic acid 16 (Scheme 2B). Compound 16 was converted to a water-soluble choline salt by treating with choline hydroxide (available commercially in methanol) in ethyl acetate to afford compound 17.

Compounds **14** and **16** did not exhibit antiviral activity, but interestingly, the choline salt **17** showed potent antiviral activity with an IC_{50} of 1.0 μ M. Prompted by the activity profile of sulfone **5**, compound **14** was similarly oxidized using potassium permanganate adsorbed on manganese dioxide to obtain sulfone ester **15**. Compound **15** was then hydrolyzed using trimethyltin hydroxide to afford carboxylic acid **18**, which was converted to the water-soluble choline salt **19** (Scheme 2A and 2B). Compound **19** also showed considerable antiviral activity, with an IC_{50} of 10 μ M.

Further SAR was performed involving: (i) nitro functionality of ring-A and sulfone as bridge A-B, which generated two compounds (Scheme 7S); (ii) combinatorial changes involving methoxy or trifluoromethoxy groups on ring-C; sulfonamide, amide, urea, or amine linkers as bridge A-B; and sulfonamide, amide or urea linkers as bridge B-C, which generated eight compounds, (Scheme 8S), and finally (iii) 7-methoxy-1H-indole and benzo[d]imidazole-2-amine were used as ring-C moieties (Scheme 9S). However, none of the compounds generated by these three schemes were active in the antiviral assays.




Figure 2: Vif antagonist small molecules enhance A3G levels and reduce Vif expression. 293FT cells co-expressing HA-tagged A3G and GFP-tagged Vif or Δ Vif were grown for 16 h in the presence of RN-18, **1** (lane c), choline chloride (lane d), **8b** (lane e), **5** (lane f), **17** (lane g), **12** (lane h), and **11** (lane i), or in the absence of compounds (lane a and b). Cell extracts were analyzed by immunoblotting with anti-HA-A3G, anti-GFP-Vif, and anti-GAPDH antibodies (see S.I. for details)

The antiviral activities of the RN-18 analogues were measured with wild-type HIV-1 in H9 cells (non-permissive) and MT-4 cells (permissive). H9 and MT4 cells (2×10^5 cells per well in 48-well plates) were treated overnight with differing concentrations of Vif antagonists (1 to 50 μ M) in Roswell Park Memorial Institute (RPMI) medium containing 10% fetal bovine serum. The cells were then infected with an X4-tropic HIV-1 variant (HIV-1_{LAI}) and

maintained for further 10-15 days (Figure 1). Viral replication was monitored every second day by measuring reverse transcriptase (RT) activity in the culture supernatants. For this, 1/3 of the culture supernatant was replaced with an equivalent volume of fresh medium containing the appropriate compounds every second day. In all experiments, RN-18 (**1**) was used as a positive control and cells cultured without compound served as negative controls. Measurements of antiviral activity in cultured cells were repeated at least 3 times (5-6 times for active compounds) and the IC_{50} values were calculated using GraFit software. The IC_{50} values for selected compounds of interest are presented in Table 1. Figure 1 shows the concentration-response curves for inhibition of viral replication by RN-18, and compounds **5**, **8a**, **8b**, and **19**. Figure 1A demonstrates that RN-18 inhibited HIV-1 replication in non-permissive H9 cells but not in permissive MT4 cells. Similarly, selective antiviral activity was exhibited by the RN-18 analogues **5**, **8a**, **8b**, and **19** (Figure 1B, C, D, and E, respectively). Antiviral activities of other RN-18 analogues of interest are presented in Table 1. Several compounds (**5**, **8b**, **11**, and **17**) showed superior antiviral activities in H9 cells compared with the lead molecule. Compound **12** showed no activity in non-permissive H9 cells.

Having demonstrated the antiviral activity of several novel Vif antagonists, we wished to determine if the analogues could upregulate A3G and downregulate Vif, as was shown for RN-18. To do this, 293FT cells co-expressing hemagglutinin (HA)-tagged A3G and green fluorescent protein (GFP)-tagged Vif or Δ Vif were grown alone or in the presence of the small molecule Vif antagonists (50 μ M) for 16 h (see supporting information for methods). The cell extracts were then analyzed by immunoblotting with anti-HA-A3G, anti-GFP-Vif, and anti-glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH) antibodies (Figure 2). In control cells grown in the absence of Vif antagonists (lane b), HA-A3G was downregulated by GFP-Vif protein. In cells treated with compounds **8b**, **5**, **17**, and **11** (lanes e, f, g, and i, respectively), HA-A3G expression was upregulated and GFP-Vif was downregulated, as was observed with cells incubated with RN-18 (lane c). Compound **12** (lane h) had no effect on A3G or Vif expression. Similarly, A3G and Vif levels were unaffected by choline chloride (lane d), suggesting that the antiviral activity of the choline carboxylate salts **17** and **19** was not due to choline itself.

The SAR trends presented in this manuscript are derived from cell-based antiviral studies. We plan to perform SAR based on the RN-18 target protein once the identification and validation of the target is complete. We expect to report those results in the near future. The presence of three aromatic rings was found to be a common structural feature of all the active analogues. A methoxy group at the *ortho* position of ring-C is preferred for activity; however, iodo (**4g**) and methane sulfonate (**4i**) groups at the *ortho* position were also tolerated without lowering the activity or specificity. Other substitutions on ring-C significantly lowered or completely eliminated the antiviral activity, with the exception of methyl carboxylate (**4f**) at the *para* position. Antiviral activity was retained when the phenyl ring-B was replaced with a pyridine ring (**8a**) and the presence of a methyl group at 6 position of the pyridine ring (**8b**) improved its activity. Replacement of the sulfide

bridge A-B (**1**) with sulfone (**5**) increased the potency about five-fold. Bridge B-C SAR showed that amide functionality is essential and its replacement with reverse amide or sulfonamides, led to an overall decrease in activity. Although our SAR results with ring-A are not yet conclusive, the carboxylic salts of choline (**17** and **19**) showed promising results.

We have performed some initial pharmacological studies with **19** and experiments with **17** are currently in progress. These studies revealed both merits and demerits of **19** (see supporting information for details). Merits include aqueous solubility (moderately soluble at the pH tested: 5.0, 6.2, and 7.2), metabolic stability (hepatic microsome stability), plasma stability, and lack of cytotoxicity (>50 μ M). Demerits include poor membrane permeability (moderately permeable at pH 5.0 and poorly permeable at pH 6.2 and 7.4), and its significant plasma protein binding. The poor membrane permeability and high plasma protein binding of **19** suggest that bioavailability of the compound may be compromised. Nonetheless, this water-soluble, non-toxic, and metabolically stable compound represents as a starting point for further development.

In conclusion, this SAR study generated several interesting RN-18 analogues (**4f**, **4g**, **4i**, **5**, **8a**, **8b**, **11**, **17**, and **19**). We briefly described some pharmacological characteristics of **19** and similar studies are underway for several compounds, including **17**. Our current studies are directed towards finding a better replacement of the amide functionality present in RN-18 and a detailed study for SAR of ring-A. A report of the ongoing studies will be communicated in the near future.

ASSOCIATED CONTENT

Experimental procedures, characterization data, and a brief summary of the pharmacological studies are given in the supporting information file. This information is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Prof. Dr. Tariq M. Rana
Program for RNA Biology,
Sanford-Burnham Medical Research Institute
La Jolla, California 92037 (USA)
Tel: +1 858 795 5325; Fax: +1 858 795 5387

*Notes

This author's name appeared as Mohd. Idrees prior to this publication.

REFERENCES

1. Ghosh, A. K.; Martyr, C. D.; Steffey, M.; Wang, Y. -F.; Agniswamy, J.; Amano, M.; Weber, I. T.; Mitsuya, H. Design, Synthesis, and X-ray

Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors. *ACS Med. Chem. Lett.* **2011**, 2, 298-302 and references therein.

2. Boyer, J.; Arnoult, E.; Médebielle, M.; Guillemont, J.; Unge, J.; Jochmans, D. Difluoromethylbenzoxazole Pyrimidine Thioether Derivatives: A Novel Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. *J. Med. Chem.* **2011**, 54, 7974-7985 and references therein.

3. Cai, Y.; Schiffer, C. A. Decomposing the Energetic Impact of Drug Resistant Mutations in HIV-1 Protease on Binding DRV. *J. Chem. Theory Comput.* **2010**, 6, 1358-1368 and references therein.

4. (a) Ali, A.; Reddy, G. S. K. K.; Nalam, M. N. L.; Anjum, S. G.; Cao, H.; Schiffer, C. A.; Rana, T. M. Structure-Based Design, Synthesis, and Structure-Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating Phenylloxazolidinones. *J. Med. Chem.* **2010**, 53, 7699-7708 and references there in. (b) Lee, T.; Le, V. -D.; Lim, D.; Lin, Y. -C.; Morris, G. M.; Wong, A. L.; Olson, A. J.; Elder, J. H.; Wong, C. -H. Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants. *J. Am. Chem. Soc.* **1999**, 121, 1145-1155.

5. Nathans, R.; Cao, H.; Sharova, N.; Ali, A.; Sharkey, M.; Stranska, R.; Stevenson, M.; Rana, T. M. Small-molecule inhibition of HIV-1 Vif. *Nat. Biotechnol.* **2008**, 26, 1187-1192.

6. Izumi, T.; Shirakawa, K.; Takaori-Kondo, A. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. *Mini Rev. Med. Chem.* **2008**, 8, 231-238.

7. (a) Sheehy, A. M.; Gaddis, N. C.; Choi, J. D.; Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* **2002**, 418, 646-650. (b) Mehle, A.; Strack, B.; Ancuta, P.; Zhang, C.; McPike, M.; Gabuzda, D. *J. Biol. Chem.* **2004**, 279, 7792-7798.

8. Shabani, A.; Mirzaei, P.; Naderi, S.; Lee, D. G. Green oxidations. The use of potassium permanganate supported on manganese dioxide. *Tetrahedron* **2004**, 60, 11415-11420.

9. (a) Kwong, F. Y.; Buchwald, S. L. A General, Efficient, and Inexpensive Catalyst System for the Coupling of Aryl Iodides and Thiols. *Org. Lett.* **2002**, 4, 3517-3520. (b) Sperotto, E.; van Klink, G. P. M.; de Vries, J. G.; van Koten, G. Ligand-Free Copper-Catalyzed C-S Coupling of Aryl Iodides and Thiols. *J. Org. Chem.* **2008**, 73, 5625-5628.

10. Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. A Mild and Selective Method for the Hydrolysis of Esters with Trimethyltin Hydroxide. *Angew. Chem. Int. Ed.* **2005**, 44, 1378-1382.

“For Table of Contents Use Only”

SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor

Idrees Mohammed, Maloy K. Parai, Xinpeng Jiang, Natalia Sharova, Gatikrushna Singh, Mario Stevenson, Tariq M. Rana*

